In conclusion, our study provides additional insights into the molecular mechanism underlying hepatic steatosis caused by miR-27b and identifies B4GALT3 and MAIP1 as potential therapeutic targets for NAFLD. Here, MAIP1 is linked to metabolic dysfunction-associated steatotic liver disease.